Venture & Growth
OrbiMed Closes $3 Billion Across Two New Funds, Splitting Its Firepower Between West and Asia
OrbiMed has closed two new private equity funds totaling $3 billion, allocating capital to life sciences in the US and Europe, and healthcare across Asia. The firm's investment strategy is shaped by AI, new therapeutic modalities, and the growth of China's biotechnology industry.
Rafael Montoya·October 16, 2026